References
- Smith GC, Pell JP, Walsh D. Pregnancy complications and maternal risk of ischaemic heart disease: a retrospective cohort study of 129,290 births. Lancet 2001;357:2002–6
- Irgens HU, Reisaeter L, Irgens LM, Lie RT. Long term mortality of mothers and fathers after pre-eclampsia: population based cohort study. BMJ 2001;323:1213–17
- Hastie CE, Smith GCS, MacKay DF, Pell JP. Maternal risk of ischaemic heart disease following elective and spontaneous pre-term delivery: retrospective cohort study of 750 350 singleton pregnancies. Int J Epidemiol 2011;40:914–19
- Ananth CV, Vintzileos AM. Ischemic placental disease: epidemiology and risk factors. Eur J Obstet Gynecol Reprod Biol 2011;159:77–82
- Maynard SE, Min JY, Merchan J, et al. Excess placental soluble FMS-like tyrosine kinase (sFlt1) may contribute to endothelial dysfunction, hypertension and proteinuria in preeclampsia. J Clin Invest 2003;111:649–58
- Agarwal I, Karumanchi SA. Preeclampsia and the anti-angiogenic state. Pregnancy Hypertens 2011;1:17–21
- Maynard SE, Karumanchi SA. Angiogenic factors and preeclampsia. Semin Nephrol 2011;31:33–46
- Tranquilli AL, Brown MA, Zeeman GG, et al. The definition of severe and early-onset preeclampsia. Pregnancy Hypertens 2013;3:44–7
- Govender L, Mackraj I, Gathiram P, Moodley J. The role of angiogenic, anti-angiogenic and vasoactive factors in pre-eclamptic African women: early- versus late-onset preeclampsia. Cardiovasc J Afr 2012;23:153–9
- Erez O, Romero R, Espinoza J, et al. The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and SGA. J Matern Fetal Neonat Med 2008;21:279–87
- Ramma W, Buhimschi I, Zhao G, et al. The elevation in circulating anti-angiogenic factors is independent of markers of neutrophil activation in preeclampsia. Angiogenesis 2012;15:333–40
- Levine RJ, Maynard SE, Qian K, et al. Circulating angiogenic factors and the risk of preeclampsia. NEJM 2004;350:672–83
- Polliotti BM, Fry AG, Saller DN, et al. Second-trimester maternal serum placental growth factor and vascular endothelial growth factor for predicting severe, early-onset preeclampsia. Obstet Gynecol 2003;10:1266–74
- Sezer SD, Kucuk M, Yenisey C, et al. Comparison of angiogenic and anti-angiogenic factors in maternal and umbilical cord blood in early-onset, and late-onset preeclampsia. Gynecol Endocrinol 2012;28:628–32
- Sundrani D, Khot V, Pisal H, et al. Gestation dependant changes in angiogenic factors and their associations with fetal growth measures in normontensive pregnancy. PLoS One 2013;8:e54153
- Romero R, Nien JK, Espinoza J, et al. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a SGA neonate. J Matern Fetal Neonatal Med 2008;21:9–23